EMN 2021 | MRD negativity and response in AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the results of a study investigating the use of next-generation flow (NGF) cytometry to detect measurable residual disease (MRD) in patients with immunoglobin light-chain (AL) amyloidosis receiving chemotherapy. The study evaluated MRD by NGF for 92 patients with AL amyloidosis who were in complete response. 54% of these patients were found to have persistent MRD. Undetectable MRD correlated with higher rates of renal and cardiac response, and progressive disease was more frequent in patients who were MRD positive. Overall, the study indicates that persistent MRD may explain persistent organ dysfunction in patients with AL amyloidosis who are in complete response, and that further treatment could be considered for MRD-persistent patients. This interview took place during the 2021 European Myeloma Network (EMN) congress.
